CD267 Polyclonal Antibody

    • Catalog No.:YT5632
    • Applications:WB;ELISA
    • Reactivity:Human;Mouse
      • Target:
      • CD267
      • Fields:
      • >>Cytokine-cytokine receptor interaction;>>Intestinal immune network for IgA production;>>Primary immunodeficiency
      • Gene Name:
      • TNFRSF13B
      • Protein Name:
      • Tumor necrosis factor receptor superfamily member 13B
      • Human Swiss Prot No:
      • O14836
      • Mouse Swiss Prot No:
      • Q9ET35
      • Immunogen:
      • The antiserum was produced against synthesized peptide derived from the Internal region of human TNFRSF13B. AA range:81-130
      • Specificity:
      • CD267 Polyclonal Antibody detects endogenous levels of CD267 protein.
      • Formulation:
      • Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
      • Source:
      • Polyclonal, Rabbit,IgG
      • Dilution:
      • WB 1:500 - 1:2000. ELISA: 1:10000. Not yet tested in other applications.
      • Purification:
      • The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
      • Concentration:
      • 1 mg/ml
      • Storage Stability:
      • -15°C to -25°C/1 year(Do not lower than -25°C)
      • Other Name:
      • TNFRSF13B;TACI;Tumor necrosis factor receptor superfamily member 13B;Transmembrane activator and CAML interactor;CD267
      • Observed Band(KD):
      • 32kD
      • Background:
      • The protein encoded by this gene is a lymphocyte-specific member of the tumor necrosis factor (TNF) receptor superfamily. It interacts with calcium-modulator and cyclophilin ligand (CAML). The protein induces activation of the transcription factors NFAT, AP1, and NF-kappa-B and plays a crucial role in humoral immunity by interacting with a TNF ligand. This gene is located within the Smith-Magenis syndrome region on chromosome 17. [provided by RefSeq, Jul 2008],
      • Function:
      • disease:Defects in TNFRSF13B are a cause of common variable immunodeficiency (CVID) [MIM:240500]. CVID is characterized by a deficiency in all immunoglobulin (Ig) isotypes. Individuals with CVID suffer from recurrent sinopulmonary and gastrointestinal infections and have an increased incidence of autoimmune disorders and of lymphoid and non-lymphoid malignancies. There is evidence for a global isotype switching defect in some individuals with CVID. But CVID is a complex and heterogeneous disease in which defects in B-cell survival, number of circulating CD27+ memory B-cells (including IgM+CD27+ B-cells), B-cell activation after antigen receptor cross-linking, T-cell signaling and cytokine expression have been observed.,disease:Defects in TNFRSF13B are a cause of immunoglobulin A deficiency 2 (IGAD2) [MIM:609529]. Selective deficiency of immunoglobulin A (IGAD) is the most common form of
      • Subcellular Location:
      • Membrane; Single-pass type III membrane protein.
      • Expression:
      • Highly expressed in spleen, thymus, small intestine and peripheral blood leukocytes. Expressed in resting B-cells and activated T-cells, but not in resting T-cells.
      • Products Images
      • Western Blot analysis of NIH-3T3 cells using CD267 Polyclonal Antibody. Secondary antibody(catalog#:RS0002) was diluted at 1:20000
      • Western Blot analysis of 3T3 cells using CD267 Polyclonal Antibody. Secondary antibody(catalog#:RS0002) was diluted at 1:20000